Clinical study about application site reaction in the oxybutynin transdermal patch
Not Applicable
- Conditions
- Overactive bladder
- Registration Number
- JPRN-UMIN000030425
- Lead Sponsor
- Suzuka University of Medical Science
- Brief Summary
Application of heparinoid cream increased skin hydration without altering transepidermal water loss. No obvious application site reaction was observed during treatment with oxybutynin transdermal patch. Overactive bladder symptom score significantly decreased during treatment (70% of patients showed a decrease of > 3 points after 12 weeks).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1)uroschesis 2)closed-angle glaucoma 3)pylorus, duodenum or intestinal tract blockage 4)paralytic ileus 5)gastric or intestinal atony 6)myasthenia gravis 7)history of oxybutynin hydrochloride hypersensitivity were excluded
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of skin barrier function Evaluation of overactive bladder symptom score
- Secondary Outcome Measures
Name Time Method Evaluation of skin barrier function The skin condition of the lower abdomen, femoral area, and lower back of the participants was evaluated before application of heparinoid cream and oxybutynin transdermal patches. Skin hydration and TEWL were evaluated using Corneometer CM825 and Tewameter TM300 core Severity of OAB was determined by OABSS. OABSS was assessed every 2 weeks from the start of oxybutynin transdermal patch treatment (week 2). OABSS decrease of >3 points during treatment period was considered effective treatment in accordance with the evaluation method described by Gotoh et al.